Circumventing Product Toxicity - Development of a Novel Two-stage Production Process for the Antibiotic Gallidermin: Spatial and Temporal Separation of Biosynthesis and Activation - Texts

Home
Main Navigation
Content
Search
Help

Font Standard Bold
Login

Research unit

INNOSUISSE

Project number

6675.1;8 BTS-LS

Project title

Circumventing Product Toxicity - Development of a Novel Two-stage Production Process for the Antibiotic Gallidermin: Spatial and Temporal Separation of Biosynthesis and Activation

Texts for this project

	German	French	Italian	English
Short description		-	-
Abstract	-	-	-

Inserted texts

Category	Text
Short description (German)	Circumventing Product Toxicity - Development of a Novel Two-stage Production Process for the Antibiotic Gallidermin: Spatial and Temporal Separation of Biosynthesis and Activation
Short description (English)	Circumventing Product Toxicity - Development of a Novel Two-stage Production Process for the Antibiotic Gallidermin: Spatial and Temporal Separation of Biosynthesis and Activation
Abstract (English)	We will investigate and develop a novel process concept for the production of gallidermin, a new type of antibiotic from Staphylococcus gallinarum with promising applications for treatment of systemic MRSA or topical Propionibacterium acne infections with a novel mode of action. Its high activity and the lack of resistance mechanisms require a completely new approach to make gallidermin production economical.